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ABSTRACT 
 
Mariya Aleksandrova Aleksandrova 
 
IMPACT OF ALCAM (CD166) ON HOMING OF HEMATOPOIETIC STEM AND 
PROGENITOR CELLS 
 
The potential of hematopoietic stem cells (HSC) to home and to anchor 
within the bone marrow (BM) microenvironment controls the ability of 
transplanted HSCs to establish normal hematopoiesis.  Activated Leukocyte Cell 
Adhesion Molecule (ALCAM; also identified as CD166), which participates in 
homophilic interactions, is expressed on a group of osteoblasts in the 
hematopoietic niche capable of sustaining functional HSC in vitro.  Since we 
could also detect ALCAM expression on HSC, we suspect that ALCAM may play 
a role in anchoring primitive hematopoietic cells to ALCAM expressing 
components of the hematopoietic niche via dimerization.  We investigated the 
role of ALCAM on the homing abilities of hematopoietic stem and progenitor cells 
(HSPC) by calculating recovery frequency of Sca-1+ALCAM+ cells in an in vivo 
murine bone marrow transplantation model.  Our data supports the notion that 
ALCAM promotes improved homing potential of hematopoietic Sca-1+ cells.  
Recovery of BM-homed Sca-1+ cells from the endosteal region was 1.8-fold 
higher than that of total donor cells.  However, a 3.0-fold higher number of Sca-
1+ALCAM+ cells homed to the endosteal region compared to total donor cells.   
 v 
Similarly, homed Sca-1+ALCAM+ cells were recovered from the vascular region 
at 2.1-fold greater frequency than total homed donor cells from that region, 
compared to only a 1.3-fold increase in the recovery frequency of Sca-1+ cells.  
In vitro quantitation of clonogenic BM-homed hematopoietic progenitors 
corroborate the results from the homing assay.  The frequency of in vitro 
clonogenic progenitors was significantly higher among endosteal-homed Sca-
1+ALCAM+ cells compared to other fractions of donor cells.  Collectively, these 
data demonstrate that engrafting HSC expressing ALCAM home more efficiently 
to the BM and within the BM microenvironment, these cells preferentially seed 
the endosteal niche.  
 
Mark G. Goebl, Ph.D., Chair 
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INTRODUCTION 
 
 Hematopoietic stem cells are multipotent progenitor cells that reside within 
a unique environment1 in the bone marrow, namely the hematopoietic niche 
(HN).  Multiple components of the HN contribute to the regulation14 of HSC 
function, including self-renewal, homing, trafficking, proliferation and 
differentiation.  While murine HSC have been well defined44, 46, 52, the complexity 
of their niche is still for the most part not fully understood50.  Attempts to define 
this compartment anatomically have been widely debated during recent years14.   
The endosteal surface and its elements, credited by many as the 
hematopoietic niche2, 4, 12, 30, consists of osteolineage cells, vascular 
endothelium, bone marrow “stromal” cells (fibroblasts, macrophages, 
adipocytes), CXCL12-expressing reticular cells and extracellular matrix proteins2.  
Others have provided genetic models47, whose design has been critisized45, but 
nevertheless, implicating perivascular and endothelial cells as the components of 
a “vascular” niche, responsible for regulating HSC behavior and function2, 47.  
Yet, no significant difference between the regulatory functions of these two bone 
marrow niches has been fully depicted23. 
It is reasonable to suspect that the wide spectrum of hematopoietic 
activities characterizing HSC may require different microenvironments19, which 
coexist in a functionally dynamic and physically interconnected setting14, 23, 32, 42.  
Therefore, anatomical segregation of sinusoids and endosteal surfaces is 
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rendered somewhat invalid when considering the proximity of these two 
“functional units”2, 14.   
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Figure 1. Integrated Bone Marrow Microenvironment Model. Adopted from 
Chitteti et al., 2010. 
 
When infused in a conditioned recipient, hematopoietic stem and 
progenitor cells (HSPC) are quickly cleared from the peripheral circulation and 
migrate rapidly towards the BM vasculature11.  Before anchoring to specialized 
niches of the BM microenvironment, HSC must go through adhesion to vascular 
endothelium, trans-endothelial migration, trans-marrow migration, and finally, 
lodgement in the HN33.  These steps describe the process of homing.  Despite 
accumulation of experimental murine and human xenotransplantation studies, 
events surrounding homing, migration, and trafficking of HSC remain ambiguous 
4, 15, 59.  Various data on the subject have emerged.  Some studies argue that 
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HSC trafficking is random and homing is not specific4.  However, multiple 
adhesion molecules expressed on primitive hematopoietic progenitors and their 
cognant receptors present on BM cellular components have been recognized to 
have a role in homing and engraftment of HSC5, 15, 35, 44. 
Taichman and Emerson first suggested that osteoblasts (OB) may play an 
important role in the regulation of human hematopoietic progenitors 25, which was 
later proven by Calvi et al.7  Accumulating evidence12, 19, 26 has been supporting 
direct association of these cells with enhanced hematopoietic function.  Others 
doubt the involvement of OB as a critical component of the HN, where vascular 
and perivascular cells41, as well as mesenchymal stem cells20 have been 
recognized in maintaining function of HSC.   
 
Figure 2. Model of support for hematopoietic stem cells by osteoblasts.19 
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 Despite the continued expansion of the list describing cellular components 
of the HN21, OB play an important role in homing.  Osteopontin secreted by these 
cells has a regulatory effect on the trans-marrow migration and lodgement of 
HSC18.  In addition, recent findings suggest that a particular subset of OB, 
expressing a novel surface molecule - ALCAM, upregulates homing-related 
genes in HSPC22 and is strongly associated with enhanced hematopoietic 
activity12, 26.   
Activated leukocyte cell adhesion molecule (ALCAM, or CD166), also 
known as hematopoietic cell antigen (HCA) is a member of the cell surface 
immunoglobulin superfamily and is involved in homophilic (ALCAM-ALCAM) as 
well as heterophilic (ALCAM-CD6) binding6.  ALCAM expression was first 
discovered on thymic epithelial cells35, and activated leukocytes6.  It is also 
expressed in most primitive CD34+ hematopoietic cells (rhodamine 123lo, Thy-1+, 
CD38-/lo) and myeloid progenitors37, perichondrium (mesenchymal stem cells) 30, 
endothelial cells29, OB38, stromal cells8, and melanoma cells60.  Recent evidence 
had recognized the role of this molecule in the homeostatic control of growth 
saturation3 and vascular invasion30, and therefore, placed significance on 
ALCAM when studying metastasis and tumor progression27, 31.  In addition, on 
account of its homophilic adhesion function, tightly regulated through the actin 
cytoskeleton36, ALCAM has been suspected to serve as a key adhesion molecule 
between primitive CD34+ hematopoietic cells and ALCAM expressing cells within 
the HN. 
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Thus, it is possible that OB may play a more direct role in anchoring and 
expanding HSC within the endosteal region of the BM via homophilic binding, 
since they also express ALCAM12, 19, 22.  Considering the evidence of enhanced 
hematopoietic function mediated by ALCAM+ OB12, 22, we examined whether 
ALCAM plays a role in homing of hematopoietic stem and progenitor cells and if 
it does, is there a preferential lodgement in the endosteal niche via homophilic 
ALCAM interactions with ALCAM-expressing OB. We investigated the role of 
ALCAM on the homing abilities of HSC by calculating recovery frequency of Sca-
1+ALCAM+ cells in an in vivo murine BM transplantation model.  To minimize 
added complexity from proliferation10 and to assess homing capabilities more 
accurately, we analyzed only short-term recovery (16 hours after injection).  In 
order to examine whether cells isolated from the endosteal region of recipients 
had increased percentage of functional donor progenitors and to investigate 
association with ALCAM, we conducted an in vitro clonogenic assay for the 
quantitation of colony forming units in parallel to a homing assay for the 
phenotypic identification of the ALCAM+Sca1+ population. 
 We hypothesized that ALCAM expression enhances homing of Sca1+ 
HSPC through anchoring of these hematopoietic cells to ALCAM expressing cells 
of the HN via dimerization.  Furthermore, we also hypothesized that HSC 
lodgement within the endosteal region may be more enhanced due to homophilic 
adhesion between ALCAM+ hematopoietic cells and ALCAM expressing OB.  
Our analysis permits observations of early HSPC homing characteristics in 
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regards to the impact of ALCAM expression on their homing and engraftment 
capabilities. 
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METHODS 
 
Mice 
Adult (6- to 8-week-old) male B6.SJL-PtrcaPep3b/BoyJ (BoyJ) mice were 
used in all experiments. In one experiment, as denoted in Figure 2, an F1 mouse 
(C57BL/6 X BoyJ) was used for the procurement of donor cells.  Animals were 
housed in the animal facility at Indiana University.  All studies were reviewed and 
approved by the Laboratory Animal Research Center of the Indiana University 
School of Medicine. 
Irradiation 
Recipient mice received a lethal dose of ionizing irradiation (950 cGy) from 
a cesium source in one fraction immediately prior to transplantation.  In some 
experiments as noted in Figure 1, some mice were not irradiated prior to 
transplantation. 
Isolation of Hematopoietic Cells from Different Marrow Regions 
 Mice were killed by carbon dioxide inhalation followed by cervical 
dislocation.  Limbs and pelvises were cleaned from muscle and connective 
tissues and femurs, tibias, humeri and iliac crests were collected for extraction of 
BM cells.  A ratio representing these bones as a percent of total bone marrow 
mass per mouse39 was used when calculating the absolute number of total BM 
cells present within a single mouse. 
Vascular Marrow Isolation. For the isolation of cells from vascular 
marrow, bones were flushed using 27-gauge needle and 13-30 ml of Iscove 
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modified Dulbecco medium supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin (1000U/ml of penicillin, 1000 ug/ml of streptomycin), and 
1% L-glutamine (GlutaMAX I, 200mM, Invitrogen).  Cells were washed by 
centrifuging at 2000 rpm for 10 minutes at 5°C.  Low-density cells were collected 
by Ficoll centrifugation (GE Healthcare).  Throughout the text, these cells would 
be referred to as vascular niche cells. 
Endosteal Marrow Isolation. After flushing, bones were cut into less than 
1-mm segments and digested by 200 U/ml of collagenase (Worthington 
Biochemical Corp., Lakewood, NJ) for 30 minutes in 37°C water bath.  Cells were 
then filtered using 30 um filter (Miltenyi Biotec, Inc., Auburn, CA) and 2-3 ml of 
PBS (Sigma-Aldrich Corp., St. Louis, MO), and washed in 20 ml of Hank’s 
Balanced Salt Solution (Invitrogen) supplemented with 10% bovine calf serum, 
1% penicillin/streptomycin (1000U/ml of penicillin, 1000 ug/ml of streptomycin).  
Low-density cells were collected by Ficoll centrifugation (GE Healthcare).  
Throughout the text, these cells would be referred to as endosteal niche cells. 
Labeling of Donor Cells with Cell Trace Violet 
Low-density bone marrow cells were labeled with CellTrace™ Violet Cell 
Proliferation Kit in order to detect donor cells in the recipients’ cell populations 
(Invitrogen, http://probes.invitrogen.com/media/pis/mp34557.pdf ).  Cells were 
labeled in vitro according to manufacturer’s specifications.   
Stem Cell Antigen (Sca-1) and ALCAM Labeling 
Cells were washed with stain wash (PBS, 1% bovine calf serum, and 1% 
penicillin-streptomycin) and stained with phycoerythrin (PE)-conjugated ALCAM 
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(eBioscience, San Diego, CA) and fluorescein isothiocyanate (FITC)-conjugated 
Sca-1 (BD Pharmingen, San Diego, CA) for 15 minutes on ice in the dark, and 
then washed again with cold stain wash.  
Sca-1 is a well-established marker for the enrichment and characterization 
of many classes of progenitor cells including fetal and adult mouse HSC48, 51, 53.  
This is why it is the basis of many models of phenotypic characterization of 
murine HSC46.  In our studies, use of additional markers to identify subsets of 
Sca1+ cells may have been problematic due to the very low16 yield of recovered 
donor BM-homed cells.  Thus, the utility of a single marker selecting for both 
hematopoietic stem and progenitor cells, such as Sca-1, allowed for a valid 
evaluation of homing potential of HSPC, represented by Sca-1+ALCAM+ cells. 
Flow Cytometric Analysis and Cell Sorting 
CTV-labeled donor cells were sorted on BD FACSAria (BD Biosciences).  
Low-density total bone marrow cells from donors and both fractions of the 
recipients’ marrow (from vascular and endosteal niche), were gated and 
analyzed for the presence of Sca-1+ALCAM+ cells on a BD LSRIII (BD 
Biosciences).  Recovery of Sca-1+ALCAM+ cells was calculated using the 
following equation: 
 
 
Recovery =  
 
 
Absolute number of recovered donor cells  
with indicated phenotype 
x 100 
Absolute number of injected donor cells  
with indicated phenotype 
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Since marrow cells contained in bones analyzed from each mouse 
represent 38% of total body marrow cellularity39, total BM-homed cells were 
estimated to be the number of CTV+ cells recovered from the bones analyzed 
multiplied by 2.63 (100/38).  ALCAM- cells have been documented to gain 
expression of the surface molecule in vitro30.  However, the possibility of this 
phenomenon to interfere with our results was excluded by our methods, since we 
did not culture prior to flow cytometric analysis.   
Progenitor Cell Assay 
 Total bone marrow cells flushed from the donor’s vascular marrow were 
plated in duplicate in 3-cm Petri dishes (BD Discovery Labware, Franklin Lakes, 
NJ) containing 1 mL of methylcellulose with cytokines (MethoCult GF M3434; 
StemCell Technologies).  This was done before and after CTV staining pre-
transplantation using 100,000 cells/plate in order to control for the effect of CTV 
staining on the viability of cells.  Plates were incubated at 37°C in a humidified 
incubator at 5% carbon dioxide.  Total donor BM cells recovered from both the 
vascular and the endosteal regions of recipient mice 16 hours post 
transplantation were sorted for CTV+ cells, and cells from both fractions were 
plated at 10,000 cells/plate as described above.  Colonies were counted on an 
inverted microscope 6-7 days after plating. 
Homing Assay 
 CTV+ low-density bone marrow mononuclear cells (< 1.084 ± 0.001 g/ml) 
were transplanted in 0.2 ml of Iscove modified Dulbecco medium supplemented 
with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% L-glutamine by 
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injection into the lateral tail vein of lethally irradiated or non-irradiated male BoyJ 
recipients as detailed in Results.  Between 1.7 x 107 and 3.5 x 107 cells were 
transplanted into each recipient immediately after irradiation. Percentages of 
donor cells recovered in marrow less than 20 hours after injection are a more 
accurate reflection of the homing potential of transplanted cells rather than their 
descendants10.  Thus, we designed the homing assay for analysis between 16 
and 20 hours post-transplantation. We will therefore refer throughout the 
dissertation to the time at which homing was assessed in transplanted mice as 
16 hours post-transplantation (16h PT).  At 16h PT, mice were killed and bone 
marrow cells flushed and collected for flow cytometric cell sorting of CTV+ cells 
and flow cytometric analysis of Sca-1+ and ALCAM+ populations.  Cells 
recovered from flushed bones represented cells that homed to the vascular niche 
of the BM.  Flushed bones were digested with collagenase as described above to 
release HCS that were anchored to elements of the endosteal region. Cells 
recovered after collagenase digestion represented cells that homed to the 
endosteal niche of the BM.  Cells released from the digested bones were also 
sorted and analyzed.   
Statistical Analysis 
 Differences between groups were analyzed using an unpaired Student’s t-
Test, where a probability value of less than 0.05 was considered statistically 
significant.  Data are expressed as the mean plus or minus SD. Excel 2003 
program (Microsoft) was used for all statistical evaluations.  A minimum of 3 
experiments were performed for each set of results. 
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RESULTS 
 
Sca-1+ALCAM + cells display an enhanced homing potential   
 Homing of HSC to the BM is a very rapid process that can be captured 
within the first 20 hours after injection of donor cells.  Transplanted stem and 
progenitor cells migrate to the BM to anchor within specialized niches and begin 
dividing, thus, repopulating the hematopoietic system.  For the short-term 
analysis of homing events, we transplanted CTV-labeled total donor cells to 
determine their absolute and relative retention within the host’s bone marrow. 
Since our hypothesis states that ALCAM promotes anchoring of HSC to elements 
of the hematopoietic niche via homophilic cell-to-cell adhesion, we expected to 
observe preferential recovery of BM-homed Sca-1+ALCAM+ cells relative to 
other cells contained in the graft. 
In order to determine the frequency of Sca-1+ALCAM+ donor population 
that homed successfully and whether spatial preference of homing does exist 
within the marrow of irradiated and nonirradiated recipient 16h PT, we analyzed 
the cells collected from the endosteal and from the vascular marrow separately.  
We examined the absolute and percent recovery of Sca-1+ALCAM+ donor cells 
and compared those to the recovery of three other phenotypes: total donor bone 
marrow mononuclear cells, total ALCAM+ cells, and total Sca-1+ cells.  As 
illustrated in Figure 1A, Sca-1+ALCAM+ cells in the vascular region of the BM 
showed increased recovery (8.35% ± 3.70) compared to total donor cells (4.0% ± 
2.0 , p < 0.05), total ALCAM+ cells (4.2% ± 1.8, p < 0.05), and total Sca-1+ cells 
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(5.2% ± 2.4, p < 0.05).  The same pattern of enhanced recovery of the Sca-
1+ALCAM + phenotype was observed within the endosteal region, where 
recovery of double positive cells was 2.2% ± 1.2.  This was significantly higher 
than the corresponding recovery of total cells (0.7% ± 0.3, p < 0.05), total 
ALCAM+ cells (1.0% ± 0.6, p < 0.05), and total Sca-1+ cells (1.3% ± 0.5, p < 0. 
05).  When recoveries from both the vascular and endosteal regions of the 
marrow were combined, we observed the same general outcome.  Recovery of 
Sca-1+ALCAM+ cells was significantly higher than that of all four phenotypes: 
total donor cells (p < 0.01), total ALCAM+ (p < 0.01), Sca-1+ALCAM + (p <0.01), 
and total Sca-1+ (p < 0.01). These data support the notion that ALCAM 
expression on Sca-1+ cells enhances homing to and retention of these 
hematopoietic cells in the BM. 
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Figure 1A. 
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Figure 1A. Enhanced homing of Sca-1+ALCAM+ cells.  
Frequency of recovered phenotypes in the vascular (blue) and endosteal (red) 
region of the bone marrow 16h PT of total BM cells into lethally irradiated 
recipients.  Sca-1+ALCAM+ cells within both regions of the marrow showed 
prominently enhanced recovery.  Recovery frequencies are calculated relative to 
the corresponding phenotype contained in the graft prior to transplantation to 
reveal the homing capability of individual phenotypically defined subsets of cells 
in the original graft.  Thus, the percentage of recovered total donor cells appears 
artificially lower than the percentage of the three phenotypes under 
consideration.  In one experiment, an F1 mouse (C57BL/6 X BoyJ) was used for 
the procurement of donor cells. In two experiments some mice were not 
irradiated prior to transplantation.  Data are presented as mean ± SD (* p < 0.05, 
relative to Sca-1+ALCAM+ cells from the Vascular region; † p < 0.05 relative to 
Sca-1+ALCAM+ cells from the Endosteal region; # p < 0.01 relative to Endosteal 
counterpart). n = 8, BMMC = bone marrow mononuclear cells. 
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The different approaches utilized in harvesting BM-homed cells from both 
regions introduced a substantial difference in yield of HSPC.  Thus, we 
represented data from Figure 1A as a fold increase in recovery of specific 
phenotypes compared to total donor cells within each BM region (Figure 1B).  
Fold increase in recovery was calculated as such: 
 
Fold increase in recovery = 
 
 Dividing results from all phenotypes by the same denominator, as 
opposed to the input frequencies of different phenotypes in Figure 1A, gave a 
clearer visualization of phenotype-related spatial preference exhibited by 
hematopoietic progenitor cells in homing.  The frequencies of BM-homed donor-
derived ALCAM+Sca-1+, total ALCAM+, and total Sca-1+ cell populations 
obtained from the endosteum were 3.0,1.3, and 1.8-fold respectively higher than 
the recovery frequency of total donor cells within that BM region.  In contrast, the 
same phenotypes of donor cell populations obtained from flushing the vascular 
marrow, were 2.1,1.1, and 1.3-fold higher than the frequency of total donor cells 
recovered in that region.  These findings support speculations of many previous 
studies10, 28, 33 by indicating that HSC in particular and primitive hematopoietic 
progenitor cells in general home and dock within the endosteal region more 
efficiently than within the vascular marrow.  Furthermore, our results illustrate 
that this pattern of spatial localization in homing may be contingent on ALCAM, 
since Sca-1+ALCAM + cell populations derived from the endosteal region of the 
Recovery frequency of indicated 
phenotype within a BM region 
Recovery frequency of total donor cells 
within a BM region 
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recipient animal displayed a prominent enrichment (3.0-fold) of progenitors 
amongst all other populations. 
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Figure 1B. 
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Figure 1B. Donor derived hematopoietic progenitors preferentially home to 
the endosteal region of the hematopoietic niche. 
Recovery of all three indicated phenotypes; Sca-1+ALCAM+, total ALCAM+, and 
total Sca-1+ cells, calculated against total recovered donor cells in each BM 
fraction.  The equation used to calculate fold increase in recovery is described on 
page 17.  Endosteal region (red); vascular region (blue). 
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 To better quantify successfully retained cells in the BM of recipient mice 
16h PT in relationship to percentages present in the graft, we evaluated relative 
homing efficiency of each phenotype using the following equation:  
 
 
Relative homing efficiency =  
 
 
 This representation of our data (Figure 1C) illustrated preferential homing 
relative to the graft itself within each region and further supported our hypothesis 
by demonstrating the prominently increased efficiency with which the BM 
successfully and specifically retains ALCAM expressing Sca-1+ hematopoietic 
precursors at 16h PT.  In this calculation, the homing efficiency for total BM 
mononuclear cells and total ALCAM+ cells is low due to the high denominator 
value for these groups of cells because of the wide representation of these cells 
in the graft.  When interpreted in the context of homing efficiency, these data 
indicate that the large number of BMMC and all ALCAM-expressing cells are 
much slower to reach the HN and home there.  Whereas, the less frequent Sca-
1+ALCAM+ group of cells which is also enriched for functional progenitors 
contributes to an enhanced relative homing efficiency.  
  
 
 
Mean percent recovery of indicated 
phenotype 
Absolute percentage of recovered 
phenotype in BM-homed cells 
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Figure 1C.  
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Figure 1C. Evaluation of phenotype specific homing abilities. 
Relative homing efficiency of indicated phenotypes in the vascular (blue) and 
endosteal (red) region of the bone marrow.  Sca-1+ALCAM+ cells within both 
regions of the marrow showed prominently enhanced homing abilities.  n = 8, 
BMMC = bone marrow mononuclear cells. 
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In vitro quantitation of colony forming units (CFU) contained in 
phenotypically defined groups of BM-homed cells 
Speculations about cells from the osteoblastic lineage playing a significant 
role in the regulation of hematopoiesis arose long time ago25.  Involvement of 
OBs in supporting HSC function was later proven in genetic models 
demonstrating that OBs are in fact active participants of the HN in vivo7.  
Hematopoietic precursors are thought to localize in close proximity to the 
endosteal surfaces9 possibly due to the presence of immature OB possessing 
strong hematopoiesis enhancement activity26 and as a result of cell-cell adhesive 
interactions19 between HSC and these immature OB.  To investigate whether 
transplanted cells isolated from the endosteal region of recipients had increased 
percentage of homed ALCAM+ progenitors, we conducted an in vitro clonogenic 
assay.  Total donor cells were plated in Methylcellulose before transplantation 
(Day 0) at a density of 105 cells per dish.  To determine the number and 
frequency of CFU in the graft, total donor cells from vascular marrow and from 
endosteum were recovered 16h PT (Day 1) through sorting of CTV+ cells and 
plated at 104 cells per dish.  Colonies were counted after 6-7 days and the 
number of colonies obtained at that time was used to express plating efficiency 
for the post-transplantation fractions (Day 1).  Pre-transplantation colonies were 
normalized to the plating cell density of the two post-transplantation fractions for 
comparison.  
A significant increase in CFU content (Figure 2) was observed in the 
fraction isolated from the recipient’s vascular marrow (10 ± 1 CFU/104 plated 
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cells) when compared to the pre-transplantation donor cells (7 ± 0 CFU/104 
plated cells , p < 0.05).  However, the greatest significant increase in CFU 
content was displayed by the fraction isolated from the host’s endosteal BM (15 ± 
1 CFU/104 plated cells) in comparison to both pre-injection (p < 0.05) and post-
injection vascular marrow (p < 0.05) donor cell fractions. 
In parallel to these experiments we conducted a homing assay to 
corroborate the results obtained in vitro and better examine homing abilities of 
hematopoietic progenitor cells in relation to ALCAM expression.  The same 
populations were analyzed by flow cytometry to determine the absolute 
frequency of Sca-1+ALCAM+ cells.  Consistent with the results obtained in vitro, 
the endosteal fraction of donor cells in the recipient showed the highest 
percentage (4.9% ± 0.6) of double positive cells when compared to recovered 
donor cells from the vascular region (3.5% ± 0.8, p < 0.05), and to cells before 
transplantation (2.1% ± 0.8, p < 0.05).  The comparison between Sca-
1+ALCAM+ frequencies in the Day 0 and the vascular Day 1 cell fractions was 
also significant, p < 0.05.   
These results illustrate a strong positive relationship between number of 
homed progenitors and frequency of Sca-1+ALCAM+ cells, which suggests that 
hematopoietic precursors were retained better within the host BM 
microenvironment when associated with ALCAM expression.  Moreover, these 
data demonstrated a selective preference for homing to the endosteum, which 
resulted in the highest enrichment of functional donor-derived progenitors in this 
niche.  
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It’s important to mention that while some investigators24 argued that 
irradiation of hosts affects distribution patterns of transplanted cells, we and 
others used nonirradiated9, 10 and irradiated recipients and still observed a 
consistent preferential distribution of hematopoietic progenitor cells within the 
endosteum (data not shown). 
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Figure 2. 
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Figure 2. Increase in homed progenitors associated with increase in Sca-
1+ALCAM+ frequency with preference for the endosteal region of the BM.  
Absolute percentage (bars) of donor Sca-1+ALCAM+ cells pre-transplantation 
(Day 0), and 16 hours post-transplantation (Day 1) isolated from vascular and 
endosteal marrow were determined by FACS analysis.  Plating efficiency (line 
graph) of the same cell populations was expressed as number of colonies 
observed on day 7 of culture in Methylcellulose at 10,000 cells per dish (the 
actual plating density for the post-transplantation fractions; the pre-
transplantation cells were normalized to that plating density).  In one experiment 
an F1 mouse (C57BL/6 X BoyJ) was used for the procurement of donor cells. 
Data are presented as mean ± SD (p < 0.05, n = 3).  
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DISCUSSION 
 
 
 
The BM microenvironment provides hematopoietic precursors with the 
factors necessary for their regulation and balance between cycling and 
quiescence to maintain a steady state of HSC self-renewal and differentiation of 
cells into all blood lineages.  The complexity of the relationship between HSC 
and their niche prompted many studies searching for major factors contributing to 
the competence of the HN.  However, complete understanding of the dynamics 
of HSC-HN interactions and how the HN participates in the regulation of HSC 
function remains illusive.  Investigations on the subject over the years has 
presented both polarizing and unifying evidence of the coexistence of two HSC 
niches – an endosteal niche comprised of functionally heterogeneous bone-lining 
cells41 and a perivascular niche consisting of the marrow vascular endothelium61.  
Initiation of hematopoiesis in the transplantation setting by infused donor cells 
relies upon their successful engraftment within the recipient’s marrow, which in 
turn depends on the homing of these donor HSC to the BM and their lodgement 
within appropriate niches4.  Currently, most of the steps and factors involving 
these processes are not fully understood and delineated. 
 Work on several adhesion molecules expressed on HSC has implicated 
their involvement in homing to the BM5.  However, limited investigation on the 
novel surface molecule ALCAM has been performed and its full impact on 
homing via homophilic interactions of ALCAM expressed on HSC and cellular 
elements of their supporting environment has not yet been defined.  We therefore 
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attempted to elucidate the role of ALCAM in homing of HSC and their retention in 
the vascular and endosteal regions of the BM microenvironment. 
 Supporting evidence of adhesive interactions between primitive human 
hematopoietic precursors, namely CD38-/lo, CD34+, Thy1+, rho123lo, and stromal 
cells in adult BM mediated by their mutual expression of ALCAM has been 
previously reported8.  Attempts at studying homing, and consequently the role of 
ALCAM in homing, however have been hampered by the inability to precisely 
determine when homing should be assessed after transplantation or which exact 
regions of the BM should be investigated for the presence of homed 
hematopoietic cells.  Even if these issues were resolved, an important parameter 
to examine in any homing study is the nature and functional capacity of BM-
homed hematopoietic cells. 
 While pursuing definitive evidence, the scientific community presently has 
accepted a hypothesis that associates the primitive long-term repopulating 
quiescent HSC with cells of the endosteum, and the more mature short-term 
repopulating HSPC with the sinusoidal endothelium7, 9, 10, 12, 17, 19, 22, 28.  This 
notion of spatial localization of HSC within the mouse endosteum was proposed 
by early studies on clonogenic progenitors and spleen colony-forming units 
(CFU-S)54.  Despite the fact that these cells are nowadays considered more 
differentiated than HSC, their increased enrichment in close proximity to the inner 
surface of the femur, paralleled by a low frequency of committed granulocytic 
progenitors54, underscored the relationship between location and developmental 
stage of hematopoietic cells.  Nilsson et al. extended that argument by 
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demonstrating that highly purified, primitive, rhodamine 123/Hoechst 33342 dull 
(Rh/Hoedull) stem cells transplanted in nonablated syngeneic recipients displayed 
strong spatial association for the endosteal BM region9.  Even though this study 
further supported an intimate association of hematopoietic early precursors with 
bone’s inner surface, it did not offer insight of the early post-transplantation 
events since it only described long-term engraftment ranging from six weeks to 
six months after injection.  In order to exclude the possibility that donor cells 
initially homed to a different location and distributed to a new area post-
proliferation, an early post-infusion analysis was required.  In addition, cell cycle 
analysis has shown that the first 40 hours post transplantation depict only events 
relating to homing alone4, since hematopoietic progenitor cells remain quiescent 
within that time window.  Thus, any observations collected within the first 20 
hours after transplanting donor cells would eliminate the complexity of 
proliferation.  For that reason we designed all of our experiments so that analysis 
was performed 16 hours post transplantation, thus ensuring we are evaluating 
only homing ability alone in association with ALCAM. 
 Nilsson et al. later confirmed that even at 15 hours after injection, 
transplanted marrow hematopoietic progenitors selectively distributed within the 
endosteal region, whereas more mature and lineage-committed cells were mainly 
found in the vascular region of the recipient’s marrow10.  Even though our 
analysis did not incorporate detailed phenotypic differentiation status, but only 
relied on identification of early hematopoietic precursors by Sca-1 expression, 
our data are consistent with these previous studies by demonstrating in vitro that 
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early post-transplantation donor progenitors distributed with greatest frequency 
within the endosteum.  Results from our clonogenic assay illustrated significant 
enrichment of donor-derived progenitors obtained from the recipient’s endosteal 
region 16h PT (Figure 2).  These cells contained a 1.5-fold higher number of 
clonogenic progenitors than their counterparts from the vascular region of the 
host’s BM.  Our data also suggest that spatial distribution of transplanted marrow 
cells is not a random phenomenon, but is rather dependent on phenotype.  The 
marked enrichment of ALCAM+ progenitors we observed in vitro in cells derived 
from the endosteum indicate that this region might facilitate an improved 
engraftment and retention of immature hematopoietic precursors. 
 While the components of the BM microenvironment contributing to the 
process of homing are still being investigated, several studies have actually 
suggested that the origin of HSC plays a role in their homing efficiency28, 33.  
Lineage- Sca-1+ c-Kit+ (LSK) HSC isolated from the endosteal region displayed 
superior homing efficiency when compared with their counterparts from the 
vascular BM28, 33.  Our protocol differed from the one utilized in the latter studies 
in the cells used for transplantation – we only injected cells derived from flushing 
the vascular marrow of the donor.  Nevertheless, we still observed superior 
retention of progenitors within the endosteum.  Our results suggest that a fraction 
of vascular marrow cells retain the ability to efficiently home to the endosteal 
niche.  Whether these cells possess an enhanced marrow repopulating potential 
relative to cells that home to the vascular niche, remains to be determined.  It is 
also reasonable to suspect that both the endosteal microenvironment and HSC 
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share a biological property that leads to a higher homing potential within that 
region.  
 In particular, adhesion molecules on cells of the osteoblastic lineage were 
suspected by Taichman et al. to be instrumental in the homing and tethering of 
HSPC to the endosteum19.  The importance of OB in regulating HSC function and 
numbers27, 55, 57, 58 through the expression of multiple factors18, 25 has already 
been established.  Evidence of the required intimate cell-to-cell contact for the 
survival of HSC in coculture with OB has been presented56 and the mechanisms 
of the homotypic ALCAM-ALCAM interactions36 have been proposed.  It is 
therefore logical to speculate that a surface marker, such as ALCAM, expressed 
on both cell types – OB and hematopoietic progenitors, acts as a homophilic 
adhesive molecule and is mediating a mechanism for high homing efficiency. 
 Indeed, two reports have illustrated elegantly the significance of ALCAM 
expressing OB in the competence of the HN12, 22.  Chitteti et al. demonstrated 
that OB exercise positive regulatory effect on LSK HSC function12.  
Nonhematopoietic Sca-1-ALCAM+ cell populations were established as the 
immature phenotype within the osteoblastic lineage12, which was associated with 
greater support of hematopoietic function26 in comparison to the more mature 
ALCAM- OB.  In the analysis of nonhematopoietic, nonendothelial BM endosteal 
cell populations, Nakamura et al. confirmed that Sca-1-ALCAM+ cells have the 
most robust enhancing activity for HSC, when compared to Sca-1-ALCAM- 
subset of OB22.  The latter report went even further into demonstrating higher 
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levels of expression of cell adhesion- and homing-related genes in hematopoietic 
precursors promoted by ALCAM+ OB. 
 Our data support the findings of both published reports12, 22 by establishing 
a clear relationship between enhanced homing of hematopoietic primitive cells 
and their expression of ALCAM.  We illustrate that recovery frequencies of Sca-
1+ hematopoietic cells from both regions of the BM are prominently increased in 
association with ALCAM expression (Figure 1A, B, and C).  These observations 
were significantly different from recovery frequencies of total ALCAM+ and total 
Sca-1+ cell populations, either of which when evaluated separately contributed 
slightly to an enhanced homing ability.   
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FUTURE DIRECTIONS 
 
While providing valuable insights on the impact of ALCAM on the 
distribution and homing of hematopoietic precursors within appropriate niches of 
the BM early post transplantation, our study did not examine long-term 
repopulating activity.  Hence, further analysis must follow in that direction to fully 
reveal the mechanism of HSC’ dependence on ALCAM.  Current research is 
being conducted (B.R.C., E.F.S.) to demarcate engraftment capability of HSC 
based on ALCAM expression by incorporating in vivo transplantation models with 
ALCAM knockout recipients and/or donors.  Early results confirm ALCAM+ HSC 
as superior in their engraftment potential compared to ALCAM- HSC (data not 
published).  In addition, the lab has demonstrated (unpublished) that LSK cells 
from ALCAM knockout mice do not engraft efficiently in wild type recipients. 
Many more questions concerning ALCAM’s mechanism of action remain 
to be answered in the future.  Further investigation through in vivo imaging and 
gene silencing studies could reveal the pathways and major factors involved in 
regulation of ALCAM expression, which is a promising approach to manipulation 
of the HN in the direction of improved long term hematopoietic reconstitution in 
the context of BM transplantation.  Establishing the exact steps in the process of 
homing – transmigration through the BM endothelium, trans-marrow migration or 
anchoring and retention in the HN, that are indeed directly affected by ALCAM’s 
action, is also an intriguing aspect of this research.  Such discovery could not 
only improve clinical outcomes in BM transplantation, but may provide a target 
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for suppression of interactions between leukemic stem cells and their supporting 
environment. 
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$15000 in annual savings. Resolved complex clinical and vendor 
problems related to the operation of analytical laboratory equipment. 
 Statistical Analysis. Collaborated with study personnel to provide input 
on study protocol. Conducted statistical data analysis and authored the 
corresponding sections of the protocol. Operated in collaboration with 
data management in the planning and implementation of data quality 
assurance programs.  Peer-reviewed other statistical documents for 
related clinical testing. 
 Regulatory and Quality Compliance. QA delegate responsibilities 
included ensuring proper documentation, compliance with GCP, 
CAP/CLIA guidelines, and competency testing.  Wrote Standard 
Operating Procedures in accordance with company’s policies and trained 
team members in updated methods. Evaluated and released quality 
control and patients’ results in LIMS system in compliance with safety 
and risk-management guidelines.  
 Communication. Communicated study results effectively via 
manuscripts and oral presentations in group settings as a member of 
interdisciplinary teams. Responded to regulatory queries. Collaborated 
with colleagues across the globe in resolving documentation and 
protocol issues. 
 
 
 
University of North Carolina Hospitals, Chapel Hill, NC  2006 - 2007 
Medical Technologist I, Core Clinical Laboratory 
 Performed clinical testing in the areas of Hematology, Urinalysis and 
Blood Gas. 
  
CERTIFICATIONS 
 Medical Technology (MT)CM, ASCP Board of Registry, 2006 
 Graduate Certificate in Biotechnology, Indiana University, Indianapolis, 
IN, 2010 
 
AFFILIATIONS 
 American Society for Clinical Pathology (ASCP), Member, 2006 - present 
 
 
 
 
 
 
 
 
 
